• Home
  • Latest
  • Fortune 500
  • Finance
  • Tech
  • Leadership
  • Lifestyle
  • Rankings
  • Multimedia
Right Arrow Button IconLeft Arrow Button IconHome
Right Arrow Button IconNovo Nordisk

Novo Nordisk

Page 2 of 9
LArs Freurgaard Jorgensen and Ursula von der Leyen pictured among Danish business leaders in 2024.
HealthEurope’s pharma titans confront von der Leyen with threat to yank $113 billion from EU and relocate to U.S. as Trump plans ‘major’ tariffs
By Ryan HoggApril 9, 2025
MagazineOzempic and Wegovy pumped $26 billion into Novo Nordisk last year. Can the pharma giant find its next breakthrough before the boom ends?
By Vivienne WaltMarch 31, 2025
FinanceSAP topples Novo to become Europe’s most-valuable listed company
By Henry Ren and BloombergMarch 24, 2025
RetailRoche, Zealand Pharma in $5.3 billion pact for obesity drugs
By Paula Doenecke, Naomi Kresge and BloombergMarch 12, 2025
FinanceNovo Nordisk CEO warns tariffs could send the prices of Ozempic and Wegovy higher
By Chris MorrisMarch 7, 2025
Semaglutide medications Wegovy and Ozempic are pictured
HealthWegovy, Ozempic shortage declared over, hitting copycats like Hims & Hers
By Bloomberg, Madison Muller, Ike Swetlitz and Naomi KresgeFebruary 21, 2025
A woman injects herself with medication.
HealthOzempic, Wegovy maker calls out Hims & Hers Super Bowl ad: ‘Check before you inject’
By Lindsey LeakeFebruary 11, 2025
Novo Nordisk President and CEO Lars Fruergaard Jorgensen testifies before the Senate Health, Education, Labor, and Pensions Committee in the Dirksen Senate Office Building on Capitol Hill on September 24, 2024 in Washington, DC. The committee heard testimony from Jorgensen about the price of popular pharmaceuticals made by Novo Nordisk that help treat diabetes and obesity, including Wegovy and Ozempic.
LeadershipAs U.S. firms scrap diversity targets, the CEO behind Ozempic and Wegovy took a pay cut for missing them
By Ryan HoggFebruary 5, 2025
Karsten Munk Knudsen, chief financial officer of Novo Nordisk A/S, at the company's headquarters in Bagsvaerd, Denmark, on Tuesday, Nov. 26, 2024.
HealthAs growth slows, CFO says Novo Nordisk is prepping for the next generation of weight loss drugs
By Ryan HoggFebruary 5, 2025
Novo Nordisk advertising logo on facade building, Danish pharmaceutical healthcare giant Novo Nordisk AS, production innovative drugs, obesity treatment Ozempic, Mainz, Germany June 15, 2024
HealthInvestors are growing anxious about Novo Nordisk’s silence since disappointing CagriSema weight loss drug results
By Ryan HoggFebruary 4, 2025
A person stands on a scale.
HealthHims & Hers Super Bowl ad slams pricey pharma industry—and fumbles FDA warnings on compounded GLP-1 drugs
By Lindsey LeakeFebruary 3, 2025
EnvironmentDeepSeek and Ozempic are complicating decarbonization forecasts
By Aaron Clark and BloombergJanuary 31, 2025
MagazineA cautionary tale that Europe can’t afford to ignore
By Alex Wood MortonJanuary 31, 2025
The increase in online searches for obesity management drugs in recent years correlated to a surge in dispensed prescriptions, according to a new study from the Johns Hopkins Ciccarone Center for the Prevention of Cardiovascular Disease.
HealthOnline searches predicted the surge in prescriptions of weight-loss drugs like Wegovy and Zepbound, study says. Here’s what could happen next
By Lindsey LeakeJanuary 29, 2025
A person, with only the midsection visible, injects Wegovy under the skin of their stomach.
FinanceNovo Nordisk stock surges 7% after Ozempic maker’s latest weight-loss drug shows promise
By Greg McKennaJanuary 24, 2025
1
  • 1
  • 2
  • 3
  • 4
  • 5
...9
Most Popular
Politics
Peter Thiel warns the Antichrist and apocalypse are linked to the ‘end of modernity’ currently happening—and cites Greta Thunberg as a driving exampleAn image of a popular article
By Nick LichtenbergFebruary 4, 2026
Success
After decades in the music industry, Pharrell Williams admits he never stops working: ‘If you do what you love everyday, you’ll get paid for free'An image of a popular article
By Emma BurleighFebruary 3, 2026
Economy
Trump may have shot himself in the foot at the Fed, as Powell could stay on while Miran resigns from White House postAn image of a popular article
By Eleanor PringleFebruary 4, 2026
Rankings
  • 100 Best Companies
  • Fortune 500
  • Global 500
  • Fortune 500 Europe
  • Most Powerful Women
  • Future 50
  • World’s Most Admired Companies
  • See All Rankings
Sections
  • Finance
  • Leadership
  • Success
  • Tech
  • Asia
  • Europe
  • Environment
  • Fortune Crypto
  • Health
  • Retail
  • Lifestyle
  • Politics
  • Newsletters
  • Magazine
  • Features
  • Commentary
  • Mpw
  • CEO Initiative
  • Conferences
  • Personal Finance
  • Education
Customer Support
  • Frequently Asked Questions
  • Customer Service Portal
  • Privacy Policy
  • Terms Of Use
  • Single Issues For Purchase
  • International Print
Commercial Services
  • Advertising
  • Fortune Brand Studio
  • Fortune Analytics
  • Fortune Conferences
  • Business Development
About Us
  • About Us
  • Editorial Calendar
  • Press Center
  • Work At Fortune
  • Diversity And Inclusion
  • Terms And Conditions
  • Site Map
  • Facebook icon
  • Twitter icon
  • LinkedIn icon
  • Instagram icon
  • Pinterest icon

© 2026 Fortune Media IP Limited. All Rights Reserved. Use of this site constitutes acceptance of our Terms of Use and Privacy Policy | CA Notice at Collection and Privacy Notice | Do Not Sell/Share My Personal Information
FORTUNE is a trademark of Fortune Media IP Limited, registered in the U.S. and other countries. FORTUNE may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.